Anti-vegf therapy

Anti-vegf therapy
Dermot McGrath
Dermot McGrath
Published: Friday, September 21, 2018
Bridging the gap between clinical trials and real-world outcomes Anti-VEGF agents have revolutionised the treatment of neovascular age-related macular degeneration, significantly reducing AMD-associated blindness and visual impairment in the process, according to Ursula Schmidt-Erfurth MD, PhD, at a special session on the EURETINA Guidelines for Management of Retinal Disease yesterday. Highlighting the achievements and challenges of current anti-VEGF therapy, Dr Schmidt-Erfurth said that intravitreal anti-VEGF therapy has significantly reduced the risk of vision loss in the major retinal diseases. “A miracle happens when we treat with a simple injection of anti-VEGF because a retina can become perfectly normal with this treatment. We know that anti VEGF therapy is beneficial for patients with a rapid, significant and maintained increase in vision and it is also beneficial for the economy given the massive investments involved,” she said. While there has been a significant improvement in therapeutic approaches to the treatment of exudative AMD in recent years, she noted that the impressive benefit of antiangiogenic therapy has not always carried over into real-world scenarios, with outcomes consistently less favourable than clinical trial results. Clinical trials have evaluated fixed one-, two- and three-monthly regimens and flexible PRN and treat-and-extend strategies, noted Dr Schmidt-Erfurth. “Many different approaches and strategies have been tried to bridge this gap between clinical trial data and real-world outcomes but the jury is still out on the optimal number to go before the monthly regimens. No decision has been made yet and there is a request for a global consensus on real world outcome measures to allow greater comparison of results. But this consensus has not been reached yet,” she said.
Latest Articles
Organising for Success

Professional and personal goals drive practice ownership and operational choices.

Read more...

Update on Astigmatism Analysis

Read more...

Is Frugal Innovation Possible in Ophthalmology?

Improving access through financially and environmentally sustainable innovation.

Read more...

From Concept to Clinic

Partnerships with academia and industry promote innovation.

Read more...

Making IOLs a More Personal Choice

Surgeons may prefer some IOLs for their patients, but what about for themselves?

Read more...

Need to Know: Higher-Order Aberrations and Polynomials

This first instalment in a tutorial series will discuss more on the measurement and clinical implications of HOAs.

Read more...

Never Go In Blind

Novel ophthalmic block simulator promises higher rates of confidence and competence in trainees.

Read more...

Simulators Benefit Surgeons and Patients

Helping young surgeons build confidence and expertise.

Read more...

How Many Surgeries Equal Surgical Proficiency?

Internet, labs, simulators, and assisting surgery all contribute.

Read more...

Improving Clinical Management for nAMD and DME

Global survey data identify barriers and opportunities.

Read more...